Technology Listings


72 Results Sort By:
HDAC Inhibitors for Managing Vascular Conditions and Diabetic Peripheral Neuropathies
Application Treatment of diabetic neuropathy using epigenetic modulators, histone deacetylase inhibitors (HDACis), to ameliorate or prevent vascular conditions and neuropathic pains by nerve damages. Key Benefits Reverses or protects against diabetes-induced nerve damages by direct injection of HDACi. Relatively low regulatory risk because many...
Published: 4/24/2020       Inventor(s): Young-Sup Yoon, Ji Woong Han, Hyunsuk Shim
Boosting Immunogenicity of Vaccines Using Saponins and Agonists of the Intracellular STING Pathway
Application Vaccine formulation of an activator of the stimulator of interferon genes (STING) pathway and saponin adjuvant for enhanced protection of aged population. Key Benefits Significantly improved protective immunity of vaccine in the aged. More efficient than the current methods of influenza vaccination of population 65 years of age or...
Published: 4/24/2020       Inventor(s): Elena Vassilieva, Richard Compans
Plant-Based Small Molecules for Treatment of MRSA Infections
Application Small molecule inhibitor of the accessory gene regulator (agr) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. Key Benefits Targeted system is non-essential for S. aureus growth, creating less selective pressure for resistance. Does not harm beneficial host bacteria. May potentially be used concomitantly...
Published: 4/23/2020       Inventor(s): Cassandra Quave, Akram Salam, Gina Porras Brenes, James Lyles
Therapeutic Compounds Inhibiting DUSP5 and DUSP6 for Cardiomyocyte Proliferation and Cardiac Regeneration
Application Therapeutics using siRNAs and small molecules to treat congenital heart defect and myocardial injuries. Key Benefits Reactivates cardiomyocyte (CM) cell replication, allowing regeneration of heart muscle after cardiac injuries. Therapeutic compounds may be administered for transient regeneration/repair of heart muscle after cardiac...
Published: 4/22/2020       Inventor(s): Ahsan Husain, Nawazish Naqvi
Small Molecule Inhibitor of Akt Activity for Lung Cancer Treatment
Application Mcl-1/Akt targeting small molecule with strong antitumor activity against lung cancer. Key Benefits Novel molecule. Novel target presents new path to lung cancer treatment. Potentially extend survival rate of lung cancer patients. Market Summary Lung cancer is the number one leading cause of death among cancer patients. Patients...
Published: 4/17/2020       Inventor(s): Xingming Deng
Chimeric Molecule for the Treatment of Depression
Application Small molecules for treating depression and/or depression associated with cancer/chemotherapy. Key Benefits Potentially a dual mechanism compound – working via monoamine reuptake inhibition and HDAC inhibition (epigenetic modification). Quicker acting compound compared to current therapies in the market. Works better than the...
Published: 4/17/2020       Inventor(s): Hyunsuk Shim, Huw Davies, Hyun Min Park, Yoon Hyeun Oum
Eradication of Pneumonococcal Carriage with Sodium Deoxycolate
Application Antibiotic use of sodium deoxycholate for preventing colonization with Streptococcus pneumoniae and treating pneumococcal infection. Key Benefits Effective against antibiotic-resistant pneumococcus. FDA-approved for use in humans. Safety already demonstrated in FDA trials for subcutaneous injection to dissolve fat deposits in humans. Market...
Published: 1/22/2020       Inventor(s): Jorge Vidal
Small Molecule for Treatment-Resistant Lung Cancer
Application Small molecule agonist for treating cancers involving KRAS mutations. Key Benefits Specifically targets mutant KRAS in non-small-cell lung carcinoma (NSCLC). Selective for mutant KRAS lung cancer cells over normal cells. Non-toxic to normal cells. Market Summary Lung cancer is the leading cause of cancer death in the US. Lung cancer...
Published: 1/14/2020       Inventor(s): Xingming Deng
Subunit-Selective NMDAR Antagonists for Treatment of Neurological Disorders
Application GluN2C/2D selective inhibitors that modulate N-methyl-D-aspartic acid receptors (NMDAR) in a subunit-selective manner for treatment of neurological disorders. Key Benefits Specifically targets NMDARs that contain the GluN2C/2D subunit. Higher potency and efficacy compared to previously reported GluN2C/2D-selective modulators. Market...
Published: 1/10/2020       Inventor(s): Yao Jing, Stephen Traynelis, Dennis Liotta
Small Molecules to Promote Bone Growth
Application Small molecule sclerostin-inhibitors to enhance the canonical Wnt pathways and promote BMP-induced osteoblast differentiation. Key Benefits Repurposing opportunities of FDA approved drugs. Lower cost compared to currently available monoclonal antibody or recombinant protein therapies. Stable compounds with established safety profiles...
Published: 12/3/2019       Inventor(s): Scott Boden, Steven Presciutti, Sreedhara Sangadala
1 2 3 4 5 6 7 8